<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05614726</url>
  </required_header>
  <id_info>
    <org_study_id>21-CAHS-102</org_study_id>
    <nct_id>NCT05614726</nct_id>
  </id_info>
  <brief_title>A Probiotic Blend Reduces Gastrointestinal Symptoms and Positively Impacts Microbiota Modulation in a Randomized Study</brief_title>
  <official_title>Effects of a Probiotic Supplement on Gastrointestinal Symptoms and Microbiome Modulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Center for Applied Health Sciences, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biohm Health, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Center for Applied Health Sciences, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, placebo-controlled, double-blind study will determine the effect of daily&#xD;
      supplementation with a probiotic blend in 60 apparently healthy men and women recruited at a&#xD;
      single investigational center in Northeast Ohio (i.e., The Center for Applied Health&#xD;
      Sciences).&#xD;
&#xD;
      Subjects will attend three study visits. During Visit 1, subjects will be screened for&#xD;
      participation [i.e., medical history, routine blood work, background baseline diet]. During&#xD;
      Visits 2 and 3 subjects will complete questionnaires that assess their gastrointestinal&#xD;
      health (e.g., abdominal discomfort/bloating, constipation, regularity, stool consistency).&#xD;
      Visits 2 and 3 will correspond to before (week 0) and after six weeks of supplementation,&#xD;
      respectively, with the probiotic dietary supplement or placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 18, 2021</start_date>
  <completion_date type="Actual">March 17, 2022</completion_date>
  <primary_completion_date type="Actual">March 17, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Flatulence (gas)</measure>
    <time_frame>Change from baseline to 6 weeks.</time_frame>
    <description>Flatulence (gas) as measured by a 10 cm visual analogue scale, where higher values represent greater flatulence.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gastro-intestinal bloating</measure>
    <time_frame>Change from baseline to 6 weeks.</time_frame>
    <description>Gastro-intestinal bloating as measured by a 10 cm visual analogue scale, where higher values represent greater bloating.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Abdominal discomfort</measure>
    <time_frame>Change from baseline to 6 weeks.</time_frame>
    <description>Abdominal discomfort as measured by a 10 cm visual analogue scale, where higher values represent greater discomfort.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gastrointestinal Symptom Rating Scale (GSRS)</measure>
    <time_frame>Change from baseline to 6 weeks.</time_frame>
    <description>Gastrointestinal problems as measured by the GSRS questionnaire, where higher values represent increased severity of gastrointestinal problems.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stool consistency</measure>
    <time_frame>Change from baseline to 6 weeks.</time_frame>
    <description>Stool consistency as measured by a 10 cm visual analogue scale, where higher values represent harder stools.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool regularity</measure>
    <time_frame>Change from baseline to 6 weeks.</time_frame>
    <description>Stool regularity as measured by a 10 cm visual analogue scale, where higher values represent more regular stools.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Constipation</measure>
    <time_frame>Change from baseline to 6 weeks.</time_frame>
    <description>Constipation as measured by a 10 cm visual analogue scale, where higher values represent more greater constipation.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Short Form Health Survey (SF-36)</measure>
    <time_frame>Change from baseline to 6 weeks.</time_frame>
    <description>Health status as measured with the SF-36 questionnaire, where scores range from 0 to 100, and higher values represent better health status.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Microbiota</condition>
  <condition>Constipation</condition>
  <condition>Candida</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Consists of 575 mg rice oligodextrin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Consists of 575mg [30 billion colony forming units probiotic blend of Bifidobacterium breve 19bx, Lactobacillus acidophilus 16axg, Lacticaseibacillus rhamnosus 18fx, Saccharomyces boulardii 16mxg, and alpha amylase</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>575mg [30 billion colony forming units] probiotic blend of Bifidobacterium breve, Lactobacillus acidophilus, Lacticaseibacillus rhamnosus, Saccharomyces boulardii, and alpha amylase</intervention_name>
    <description>A multi-strain probiotic blend</description>
    <arm_group_label>Active</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  all participants were required to be between 30-60yr&#xD;
&#xD;
          -  score ≥12 on the GSRS&#xD;
&#xD;
          -  have a body mass ≥120 pounds (54.5kg)&#xD;
&#xD;
          -  body mass index (BMI) between 20.0-34.99kg/m2&#xD;
&#xD;
          -  normotensive (&lt;140/&lt;90mmHg)&#xD;
&#xD;
          -  normal resting heart rate (&lt;90bpm)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Female participants who were pregnant or nursing&#xD;
&#xD;
          -  history of unstable or new-onset cardiovascular or cardiorespiratory disease;&#xD;
&#xD;
          -  stroke, diabetes, or other endocrine disorder;&#xD;
&#xD;
          -  use of any nutritional supplement known to alter the gut microbiota/microflora;&#xD;
&#xD;
          -  use of probiotic supplements or prebiotic supplements in the previous 4 weeks and for&#xD;
             the duration of the study;&#xD;
&#xD;
          -  use of any antibiotics, antifungals, antivirals, or antiparasitic within 8 weeks of&#xD;
             the start of the study or throughout the study;&#xD;
&#xD;
          -  any changes in diet within 4 weeks of study start date or throughout study duration;&#xD;
&#xD;
          -  if the participant was unwilling to abstain from gut altering supplements for the&#xD;
             study;&#xD;
&#xD;
          -  malignancy in the previous 5yr except for non-melanoma skin cancer (basal cell cancer&#xD;
             or squamous cell cancer of the skin);&#xD;
&#xD;
          -  prior gastrointestinal bypass surgery (i.e., Lapband);&#xD;
&#xD;
          -  any known gastrointestinal or metabolic diseases that might impact nutrient absorption&#xD;
             or metabolism [e.g. short bowel syndrome, diarrheal illnesses, history of colon&#xD;
             resection, gastroparesis, Inborn-Errors-of-Metabolism (such as PKU)];&#xD;
&#xD;
          -  any chronic inflammatory condition/disease (e.g. rheumatoid arthritis, Crohn's&#xD;
             disease, ulcerative colitis, Lupus, HIV/AIDS, etc.);&#xD;
&#xD;
          -  known sensitivity to any ingredient in the test formulations as listed in the&#xD;
             certificates of analysis.&#xD;
&#xD;
          -  currently participating in another research study with an investigational product or&#xD;
             had participated in another research study in the past 30 days&#xD;
&#xD;
          -  any other diseases/conditions that, in the opinion of the medical staff, could&#xD;
             confound the primary endpoints or place the subject at increased risk of harm if they&#xD;
             were to participate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Center for Applied Health Sciences</name>
      <address>
        <city>Canfield</city>
        <state>Ohio</state>
        <zip>44406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 5, 2022</study_first_submitted>
  <study_first_submitted_qc>November 11, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2022</study_first_posted>
  <last_update_submitted>November 11, 2022</last_update_submitted>
  <last_update_submitted_qc>November 11, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

